Teva Pharmaceutical (TEVA) Received Neutral By Cantor Fitzgerald with $31.00 Target, Shorts at Viavi Solutions (VIAV) Raised By 9.12%

June 19, 2017 - By Dolores Ford

Among 25 analysts covering Teva Pharma (NYSE:TEVA), 13 have Buy rating, 0 Sell and 12 Hold. Therefore 52% are positive. Teva Pharma has $86 highest and $25 lowest target. $55.50’s average target is 79.50% above currents $30.92 stock price. Teva Pharma had 60 analyst reports since July 21, 2015 according to SRatingsIntel. The company was initiated on Friday, February 19 by Wells Fargo. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Buy” rating by Deutsche Bank on Tuesday, July 28. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Neutral” rating by Bank of America on Monday, November 7. Oppenheimer maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) rating on Thursday, July 14. Oppenheimer has “Outperform” rating and $72 target. RBC Capital Markets maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Wednesday, November 16 with “Outperform” rating. The rating was maintained by Deutsche Bank with “Buy” on Wednesday, November 16. The firm has “Market Perform” rating by Wells Fargo given on Monday, January 9. The firm has “Outperform” rating given on Thursday, March 30 by Maxim Group. On Monday, November 23 the stock rating was upgraded by Goldman Sachs to “Buy”. The stock has “Buy” rating by Jefferies on Friday, October 30.

Viavi Solutions Incorporated (NASDAQ:VIAV) had an increase of 9.12% in short interest. VIAV’s SI was 11.84 million shares in June as released by FINRA. Its up 9.12% from 10.85M shares previously. With 4.99 million avg volume, 2 days are for Viavi Solutions Incorporated (NASDAQ:VIAV)’s short sellers to cover VIAV’s short positions. The stock increased 2.45% or $0.27 on June 16, reaching $11.31. About shares traded. Viavi Solutions Inc (NASDAQ:VIAV) has risen 77.76% since June 19, 2016 and is uptrending. It has outperformed by 61.06% the S&P500.

The stock increased 1.66% or $0.5 during the last trading session, reaching $30.92. About 2,936 shares traded. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 41.70% since June 19, 2016 and is downtrending. It has underperformed by 58.40% the S&P500.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The company has market cap of $32.69 billion. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. It has a 292.66 P/E ratio. The Firm operates through two divisions: Generic medicines and Specialty medicines.

Viavi Solutions Inc. is a provider of network test, monitoring and assurance solutions to communications service providers, enterprises and their ecosystems. The company has market cap of $2.63 billion. The Firm also offers thin film optical coatings, providing light management solutions to anti-counterfeiting, consumer and industrial, government and healthcare and other markets. It has a 30.3 P/E ratio. The Company’s divisions include Network Enablement (NE), Service Enablement (SE), and Optical Security and Performance Products (OSP).

Among 7 analysts covering Viavi Solutions Inc (NASDAQ:VIAV), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Viavi Solutions Inc had 13 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Viavi Solutions Inc (NASDAQ:VIAV) has “Buy” rating given on Wednesday, August 12 by Craig-Hallum. The stock has “Outperform” rating by RBC Capital Markets on Monday, August 10. The stock of Viavi Solutions Inc (NASDAQ:VIAV) has “Buy” rating given on Thursday, August 13 by UBS. The stock has “Hold” rating by Craig Hallum on Wednesday, August 12. The rating was upgraded by B. Riley & Co to “Buy” on Wednesday, August 5. The rating was upgraded by JP Morgan to “Overweight” on Tuesday, October 11. M Partners maintained the shares of VIAV in report on Monday, June 6 with “Buy” rating. The stock has “Outperform” rating by William Blair on Friday, August 14. Jefferies maintained the shares of VIAV in report on Friday, August 14 with “Hold” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: